Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04671953 · ClinicalTrials.gov registry record · Phase 1

Effect of BMS-986165 on the Blood Levels of Metformin

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT04671953 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04671953, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the effects of BMS-986165 on the drug levels of metformin in healthy participants.

Interventions

  • DRUG Metformin
  • DRUG BMS-986165

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2020-12-18
Est. Completion 2021-03-30
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT04671953

The ClinicalTrials.gov registry entry for NCT04671953 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.

NCT04671953 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04671953 about?

NCT04671953 is a clinical study titled "Effect of BMS-986165 on the Blood Levels of Metformin". The purpose of this study is to investigate the effects of BMS-986165 on the drug levels of metformin in healthy participants.

What is the current status of trial NCT04671953?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-12-18. Estimated completion is 2021-03-30.

What interventions are being tested in trial NCT04671953?

The interventions under investigation include: Metformin (DRUG), BMS-986165 (DRUG).

Who is sponsoring clinical trial NCT04671953?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.